This clinical brief was sponsored by LEO Pharma Inc.
Clinical and Economic Value of Tralokinumab (ADBRY®) for Patients With Moderate to Severe Atopic Dermatitis
Advertisement
Advertisement
Trending on AJMC
1
DOJ Abandons Olmstead Defense as Texas v Kennedy Advances
2
FDA Expands Tirzepatide Label to Reduce Cardiovascular Risk in Type 2 Diabetes
3
Myasthenia Gravis Linked to Greater Longevity Than Multiple Sclerosis
4
FDA Approves Rusfertide to Treat Erythrocytosis In Polycythemia Vera
5